HomeMarketsEarningsNVO Earnings In Focus: Weight Loss Drugs, Combatting Copy Cats

NVO Earnings In Focus: Weight Loss Drugs, Combatting Copy Cats

Kyle Bergacker joins Sam Vadas to discuss Novo Nordisk (NVO) earnings. Shares of the biotech pharmaceutical company are down following its 2Q report. Kyle discusses the lowered sales growth in its guidance as well as combatting "copy cat" medications from telehealth companies. He adds commentary on the company's GLP-1 weight loss drugs and what it means in regards to the long-term outlook for Novo Nordisk.

Morning Movers

06 Aug 2025

SHARE

ON AIR
education
2:00 am
Your First Trade
replay
12:00 am
Market Overtime
REPLAY
12:30 am
Market On Close
REPLAY
ON AIR
education
2:00 am
Your First Trade
REPLAY
education
2:30 am
Your First Trade
REPLAY
3:00 am
Fast Market
REPLAY
4:00 am
Next Gen Investing
REPLAY
5:00 am
Market Overtime
REPLAY
5:30 am
The Wrap
REPLAY
7:00 am
Morning Movers
8:00 am
Opening Bell With Nicole Petallides
9:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
2:00 pm
Market On Close
3:30 pm
Market Overtime
REPLAY
4:00 pm
Fast Market
REPLAY
5:00 pm
Next Gen Investing
REPLAY
6:00 pm
The Wrap
REPLAY
education
7:30 pm
Liz Ann Live
REPLAY
8:00 pm
Market Overtime
REPLAY
8:30 pm
Market On Close
REPLAY
education
10:00 pm
Liz Ann Live
REPLAY
10:30 pm
The Wrap
REPLAY

Schwab Network's Newsletters

Daily insights for every investor